Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombotic therapy

P J Schubert1, J Loscalzo

  • 1Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, Massachusetts, USA.

Comprehensive Therapy
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DeepFocus: fast focus and astigmatism correction for electron microscopy.

Nature communications·2024
Same author

Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma.

Clinical pharmacology and therapeutics·2019
Same author

Developing new drug treatments in the era of network medicine.

Clinical pharmacology and therapeutics·2012
Same author

Detection of nitrosated proteins.

Current protocols in toxicology·2012
Same author

Cellular hypomethylation is associated with impaired nitric oxide production by cultured human endothelial cells.

Amino acids·2011
Same author

The antithrombotic effects of organic nitrates.

Trends in cardiovascular medicine·2011

New direct thrombin inhibitors offer safer and more effective antithrombotic therapies. These advanced agents promise improved treatment for thromboembolic disorders and cardiovascular diseases, potentially replacing older, less selective drugs.

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Hematology

Background:

  • Antithrombotic therapy has advanced significantly, with numerous agents now available.
  • Thrombin inhibitors are crucial for managing thromboembolic disorders.
  • Existing indirect inhibitors like heparin and warfarin present clinical challenges due to side effects and lack of selectivity.

Purpose of the Study:

  • To review the evolution of antithrombotic therapies.
  • To highlight the therapeutic potential of direct thrombin inhibitors.
  • To discuss the advantages of selective thrombin inhibition over traditional agents.

Main Methods:

  • Literature review and analysis of existing antithrombotic agents.
  • Comparison of the mechanisms of action, efficacy, and safety profiles of indirect versus direct thrombin inhibitors.

Related Experiment Videos

  • Discussion of clinical implications for cardiovascular disease management.

    • Main Results:

    • Standard indirect inhibitors (heparin, warfarin) have limitations including nonhemostatic side effects and nonselectivity.
    • Direct thrombin inhibitors offer a more selective mechanism of action.
    • These newer agents demonstrate potential for improved safety and efficacy.

    Conclusions:

    • Direct thrombin inhibitors are poised to supplement or replace current therapies.
    • Selective thrombin inhibition represents a promising advancement in preventing and treating thrombosis.
    • This approach may lead to safer and more effective management of cardiovascular diseases.